Efficacy of Fampridine on Refractory Optic Neuritis in Neuromyelitis Optica Spectrum Disorders
In a study involving patients aged 14-80 with AQP4-IgG positive optic neuritis, those receiving 4-AP (sustained-release fampridine) showed greater improvements in visual function (VFS and OSIS) over 6 months compared to controls. At 3 months, more patients on 4-AP had significant visual improvements compared to those not on it (36.4% vs. 7.1%).
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
These findings suggest that fampridine could enhance visual recovery in specific cases of optic neuritis, potentially offering new treatment options for affected patients.
What this does not prove
The study's focus is on a specific condition (AQP4-IgG positive ON), limiting the applicability of results to broader optic neuritis cases. Additionally, the long-term effects of fampridine on visual function are not yet known.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-27
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Patients aged 14-80 with acute refractory AQP4-IgG positive ON
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceEfficacy of Fampridine on Refractory Optic Neuritis in Neuromyelitis Optica Spectrum Disorders. ↗DOI: 10.1002/acn3.70557
Supporting passages (12)
publication date2026-10-27
interventionsustained-release fampridine (4-aminopyridine, 4-AP)
comparatornon-4-AP
primary endpointVisual functional scores (VFS), Opticospinal Impairment Scale (OSIS)
follow up6 months
findingsPatients with 4-AP add-on treatment improved VFS or OSIS greater than that with control (non-4-AP) at 3 and 6 months compared with baseline (all p < 0.05).
findings4-AP add-on treatment also increased the proportion of better improvement of ON (VFS ≤ 2) at 3 months (36.4% vs.
findings4-AP improved visual field at 6 months (p < 0.05 adjusted for plasma exchange).
populationMETHODS: Patients aged 14-80 who suffered from acute refractory AQP4-IgG positive ON within 2 weeks onset and with high-dose corticosteroid treatment were included.
limitationsTitle: Efficacy of Fampridine on Refractory Optic Neuritis in Neuromyelitis Optica Spectrum Disorders.
peer reviewedPublication types: Journal Article
subjectsMETHODS: Patients aged 14-80 who suffered from acute refractory AQP4-IgG positive ON within 2 weeks onset and with high-dose corticosteroid treatment were included.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.